Cargando…

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine

BACKGROUND: Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C™), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verreault, Maite, Strutt, Dita, Masin, Dana, Anantha, Malathi, Yung, Andrew, Kozlowski, Piotr, Waterhouse, Dawn, Bally, Marcel B, Yapp, Donald T
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080346/ https://www.ncbi.nlm.nih.gov/pubmed/21477311 http://dx.doi.org/10.1186/1471-2407-11-124

Ejemplares similares

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities
por: Waterhouse, Dawn N., et al.
Publicado: (2014)

Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil
por: Hare, Jennifer I., et al.
Publicado: (2013)

Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model
por: Verreault, Maite, et al.
Publicado: (2013)

Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx(®)) as Pressurized Intraperitoneal Aerosol Chemotherapy
por: Robella, Manuela, et al.
Publicado: (2019)

High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours
por: Koukourakis, M I, et al.
Publicado: (2000)

(99m)Tc-labelled Stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Laverman, P, et al.
Publicado: (2002)

Reply: (99m)Tc-labelled Stealth liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Koukourakis, M I
Publicado: (2002)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
por: Webb, M. S., et al.
Publicado: (1995)

Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts
por: Eikenes, L, et al.
Publicado: (2005)

Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.
por: Mayer, L. D., et al.
Publicado: (1995)

A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx (®) in advanced breast cancer
por: Li, Yinjuan, et al.
Publicado: (2022)

Pegylated Liposomal Doxorubicin (Caelyx(®)) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial
por: Dellapasqua, Silvia, et al.
Publicado: (2021)

Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
por: Ju, Hee Young, et al.
Publicado: (2022)

Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma
por: Susa, Michiro, et al.
Publicado: (2009)

Comparative plasma and tissue distribution of Sun Pharma’s generic doxorubicin HCl liposome injection versus Caelyx(®) (doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB/c mice and Sprague–Dawley rats
por: Burade, Vinod, et al.
Publicado: (2017)

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
por: DuBois, S G, et al.
Publicado: (2015)

Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models
por: Burade, Vinod, et al.
Publicado: (2017)

A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors
por: Venkatramani, Rajkumar, et al.
Publicado: (2013)

Mechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells.
por: Souès, S., et al.
Publicado: (1995)

Irinotecan and vincristine for the treatment of refractory desmoplastic small round cell tumor in a developing country: a case report
por: Ambar, Natalia Brenneken Duarte, et al.
Publicado: (2019)

A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas
por: Russo, Ida, et al.
Publicado: (2020)

Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
por: Casanova, Michela, et al.
Publicado: (2023)

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
por: Wardley, A. M., et al.
Publicado: (1998)

Lymph cancer chemotherapy: delivery of doxorubicin–gemcitabine prodrug and vincristine by nanostructured lipid carriers
por: Ni, Shuqin, et al.
Publicado: (2017)

Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma
por: Zhang, Yue, et al.
Publicado: (2017)

Biodegradable nanoparticulate co-delivery of flavonoid and doxorubicin: Mechanistic exploration and evaluation of anticancer effect in vitro and in vivo
por: Khan, Iliyas, et al.
Publicado: (2021)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

Nanoparticulate systems for polynucleotide delivery
por: Basarkar, Ashwin, et al.
Publicado: (2007)

Mercury Reduction by Nanoparticulate Vivianite
por: Etique, Marjorie, et al.
Publicado: (2021)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two‐Cohort, Phase Ib/II Trial
por: Xu, Jie, et al.
Publicado: (2021)

Marqibo(®) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
por: Silverman, Jeffrey A., et al.
Publicado: (2012)

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)
por: Poveda, A., et al.
Publicado: (2005)

The Effects of Vincristine and Doxorubicin on the Clonogenic Cells of a Human Lung Cancer Cell Line in Methylcellulose and Suspension Culture
por: Yamashita, Yoko, et al.
Publicado: (1989)

Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy
por: Matsukawa, Toshihiro, et al.
Publicado: (2018)

L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma
por: Lee, Jih-Jong, et al.
Publicado: (2021)

Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report
por: Hojo, Nobumasa, et al.
Publicado: (2022)

Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol
por: Miyachi, Mitsuru, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lfv9c1j15aq2g1ilc7aronqc3n